How did Eli Lilly's sales costs evolve in Q2 2024?

Eli Lilly's sales costs for Q2 2024 are not currently available. However, we can infer some trends from the available data.

1. Overall Increase in Sales and Marketing Expenses: Lilly's sales and marketing expenses increased by 12% in Q1 2024, totaling $1,952.2 million. This indicates a general upward trend in sales-related costs.
2. Specific Drug Sales Contributions: The sales of Mounjaro and Zepbound were particularly strong, with Mounjaro sales more than tripling and Zepbound sales amounting to $517 million. These drugs were key drivers of the company's revenue growth.
3. Supply Issues Impact: Despite the strong demand, Lilly faced supply issues, which could have temporarily impacted sales and marketing efforts. However, the company anticipated that production increases would occur in the latter half of the year, suggesting that sales costs may increase alongside increased production.

In conclusion, Eli Lilly's sales costs in Q2 2024 were likely higher than the previous year, primarily due to the increased sales of Mounjaro and Zepbound. The company's overall sales and marketing expenses showed a positive trend, but the impact of supply issues was a notable factor.